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This paper focuses on oncolytic Newcastle disease virus (NDV). This paper summarizes (i)
the peculiarities of this virus as an anti-cancer and immune stimulatory agent and (ii) the
approaches to further harness this virus as a vector to combat cancer. Special emphasis
is given on combining virus therapy with cell therapy and on improving tumor targeting.
The review will include some of the authors work on NDV, bi-specific antibodies, and cell
therapy as building blocks for a new perspective of multimodal cancer therapy. The broad
anti-tumor immune reactivation includes innate and adaptive, tumor antigen (TA) specific
and TA independent activities
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INTRODUCTION
Paramyxoviruses are a family of viruses that infect a diverse
range of hosts. Animal pathogens, such as Newcastle disease virus
(NDV), SV-5, and Sendai virus (SV), have been major subjects for
basic research by virologists, immunologists, and molecular biol-
ogists. Previously, genetic manipulation of paramyxoviruses was
not possible because the genome is not infectious alone and RNA
recombination is essentially non-existent. During the last 15 years,
methods of producing infectious paramyxoviruses from c-DNA
clones (reverse genetics) have been developed. This review will
focus on NDV, an avian paramyxovirus, because this has a num-
ber of very interesting anti-neoplastic and immune stimulating
properties in mammalian cells, including human being, because it
has a high safety profile for clinical application and because it can
be harnessed by therapeutic transgenes.
NEWCASTLE DISEASE VIRUS, TRANSGENES, AND
BI-SPECIFIC ANTIBODIES
ONCOLYTIC PROPERTIES OF NATURAL STRAINS OF NDV
Vaccine strains of paramyxoviruses such as mumps virus (MuV),
measles virus (MV), and NDV efficiently infect and kill cancer cells
and are consequently being investigated as novel cancer therapies
(oncolytic virotherapy) (1). NDV wildtype (wt NDV) virus shows
naturally tumor selective replication behavior (2). An abortive
replication cycle by lentogenic strains leads eventually to tumor cell
death. A lytic replication cycle by mesogenic or velogenic strains
leads to fast tumor cell death (oncolysis) and further spread of the
virus in the tumor tissue. The strong interferon (IFN) response
of normal cells (2) prevents virus replication and cell death thus
explaining the high safety record of NDV in cancer patients (3).
There are additional properties that make NDV a particularly
interesting anti-neoplastic agent. It replicates and destroys in par-
ticular cancer cells that are resistant to certain types of chemother-
apy (4–6) and apoptosis-resistant tumor cells from hypoxic tumor
tissue (7). The oncogenic protein Rac1 was reported as a link
between tumorigenesis and sensitivity of cells to oncolytic NDV
(8). Furthermore, NDV triggers autophagy in glioma cells (9) and
promotes Bax redistribution to mitochondria and cell death in
HeLa cells (10). A time-course analysis revealed that NDV-induced
apoptosis involved an early extrinsic pathway with TRAIL expres-
sion (peak at 24 h p.i.) and a later intrinsic mitochondrial pathway
(peak at 48 h p.i.) (11).
NDV was reported to repress the activation of human hepatic
stellate cells and reverse the development of hepatic fibrosis in
mice (12). Liver fibrosis is a major health problem and the 12th
most common cause of death in the United States (13).
HARNESSING NDV BY TRANSGENES AND BI-SPECIFIC ANTIBODIES
Recombinant NDV strains (rNDV) could be harnessed by trans-
genes to show enhanced oncolytic potential. This was achieved
by F gene mutations (14, 15) or by addition of the NS1 (16) or
Apoptin (17) gene. It could also be harnessed by genes coding for
cytokines, such as IL-2 (18), GM-CSF (19), IL-15 (20), or IFN-γ
(21) to express enhanced immune stimulatory properties. Other
transgenes conferred resistance to complement (22). NDV was also
capable of incorporating two transgenes, one coding for the light
chain and the other for the heavy chain of a monoclonal antibody
interacting with angiogenesis (23). The transfer of a gene coding
for a tumor antigen (TA) created a vector with which the immune
response could be targeted to a specific TA in order to compete with
the usually stronger response to viral antigens (VA) (24). A recom-
binant oncolytic MV (MV-AC133) could be targeted to CD133+
cancer-initiating cells causing their specific elimination (25).
To augment the immune stimulatory properties of NDV
infected tumor cells, another elegant approach was successful. It
consists of the attachment of single-chain variable fragment (scFv)
bi-specific antibodies (bsAbs). These attach with one arm to a VA
and with the other arm to a target on immune cells. In case of
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T-cells, such targets were CD3 (26), CD25 (27), and CD28 (28).
The VAs of NDV were either HN or F. These served as universal
anchor molecules through which T-cell co-stimulatory molecules
could be attached to any type of tumor cell infectable by NDV (29).
In the following paragraph, we will present a perspective how
such bsAbs can be further used in a multimodal approach for
improvements of cancer therapy.
FUTURE PERSPECTIVE: COMBINING NDV WITH bsAbs AND
WITH ADOPTIVE CELLULAR THERAPY
TUMOR TARGETING OF NDV
A major problem with the clinical application of oncolytic viruses
is a proper targeting of tumor tissue. This can be achieved by intra-
tumoral application (30) but metastases are often not accessible
by this approach. Nevertheless, localized oncolytic virotherapy
was reported to overcome systemic tumor resistance to immune
checkpoint blockade immunotherapy (31).
Locoregional application (e.g., via the hepatic vain) was
reported to be superior to systemic tail vain inoculation (32).
Locoregional virotherapy was effective even against oncolysis-
resistant tumor cells, thus suggesting that the anti-tumor effect
was host mediated (32). Inhalation is another way of locore-
gional application. Inhalation of oncolytic NDV was applied to
33 advanced chemorefractory patients in a Phase II clinical study
in Hungary as a means to affect their lung metastases (33).
Virus inoculation into body cavities in case of tumor ascites is
another way of locoregional application. For instance, intraperi-
toneal NDV virotherapy was effective against peritoneal carcino-
matosis from human gastric cancer in a xenograft model (34)
and intrapleural NDV virotherapy induced sustained remission of
malignant pleural mesothelioma in an orthotopic model (14).
Upon systemic administration of NDV, its binding to normal
cells could prevent it from reaching the tumor tissue and could
cause undesired side effects. Since efficient distribution at the
tumor site may be a very critical parameter for tumor selective
gene delivery and for anti-tumor efficacy of oncolytic virotherapy
(35), we have developed adaptor molecules that redirect the virus
to tumor tissue (36). The targeting molecule used, anti-HN-IL-2,
contains a scFv antibody cloned from a neutralizing HN specific
hybridoma linked to the human gene for the cytokine IL-2. Selec-
tive virus entry was observed in vitro in a mixture of IL-2 receptor
positive and negative human tumor cells (37). Retargeted virus
infection of tumor cells required specific binding via the bi-specific
fusion protein and membrane fusion via the viral F-protein. After
systemic virus inoculation into tumor-bearing mice, the modifi-
cation of NDV by the adaptor protein did not compromise the
efficiency of gene delivery into target positive tumors but greatly
reduced viral gene expression in target negative tumors and in
normal tissues thereby reducing side effects (38).
UNIVERSAL ACTIVATION OF CANCER PATIENTS T-CELLS (NAÏVE AND
MEMORY) VIA TUMOR CELL-BOUND BI-SPECIFIC ANTIBODIES
Infection of tumor cells by NDV leads to increase in tumor
cell immunogenicity (39). A prospective, randomized, controlled
clinical study of post-operative immunization with the autol-
ogous tumor vaccine ATV-NDV revealed evidence for clini-
cal effectivity and long-term survival for colon cancer patients
(40). Further augmentation of T-cell stimulatory capacity of
the ATV-NDV vaccine was achieved by attachment of specifi-
cally designed bsAbs binding to viral HN or F on the infected
tumor cells and to CD3 or CD28 on T-cells (41). The opti-
mized vaccine ATV-NDV/bsHNxCD3/bsHNxCD28 appeared to
be able to revert unresponsiveness of partially anergized TA-
specific T-cells (42). It was also capable of de novo activation
of anti-tumor activity from naïve T-cells, independent of TA
recognition (Figure 1A) (42). The strongest potentiation of the
T-cell stimulatory capacity of the ATV-NDV vaccine was observed
upon attachment of a suboptimal amount of bsHNCD3 together
FIGURE 1 | Activation of naïve humanT-cells by co-incubation with
NDV infected irradiated tumor cells modified with bi-specific or
tri-specific antibodies. (A) Time course of the induction of T-cell activation
and proliferation by a stimulatory cell (NDV infected and y-irradiated tumor
cells) optimized for co-stimulation by attachment of the bi-specific fusion
proteins anti-CD3 (anti-HNxanti-CD3) and anti-CD28 (anti-HNxantiCD28).
Purified and CFSE-labeled naïve human T-cells were cocultivated for 5 or
7 days with the stimulatory cells. The CFSE signal intensities were
compared with unstimulated cells by FACS analysis. We also followed by
the FACS analysis the expression of the IL-2 receptor α chain (CD25) and of
the memory marker CD45RO. (B) Diagram of the components of a tumor
vaccine infected by NDV and modified by a bi-specific antibody
(anti-HNxanti-CD3, suboptimal amount for signal 1) and a tri-specific
immunocytokine (anti-HNxIL-2xanti-CD28, for delivery of two T-cell
co-stimulatory signals via CD28 and CD25).
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with the tri-specific (ts) fusion protein tsHNxIL-2xCD28. The lat-
ter delivers two co-stimulatory signals to T-cells, one via CD28
and the other via CD25 (26). Figure 1B illustrates the modu-
lar concept of the tumor vaccine infected by NDV and modified
by bsAbs.
We suggest to use T-cell activation one universal GMP tumor
cell line for patients. This will be modified by infection with NDV
and by attachment of the above bsAbs and tsAbs. This universal
T-cell stimulatory cell can be applied for non-specific activation
of anti-tumor activity of T-cells from any type of cancer patient
and is independent from a TA.
PROGRAMING OF CANCER PATIENTS DENDRITIC CELLS TOWARD DC1
VIA INFECTION BY NDV
We reported on polarization of human monocyte-derived DCs
to DC1 by in vitro stimulation with NDV (43). Also, murine
DCs upon infection by NDV differentiate into the immunogenic
phenotype DC1 characterized by secretion of pro-inflammatory
cytokines, in particular IL-12 and IFN-α and -β (44). Two receptor-
initiated signaling cascades were involved: the first one is induced
by triggering and upregulation of the intra-cellular cytoplas-
mic receptor RIG-1 upon recognition of viral non-capped RNA
as ligand (45). The second signal cascade involves cell-surface
expressed type I IFN receptor (IFNAR), which initiates a feed-
back loop cell activation upon interaction with extra-cellular type
I IFN as ligand (31, 44). RIG-1/RNA ligand interaction not only
activates type I IFN, but also induces inflammasome activation
for IL-1β production (46). Type I IFN and IL-12 are critical
mediators of cross-priming and Th1 polarization of CD8 T-cell
responses (47) while IL-1β is critical for Th1 polarization of CD4
T-cells (48).
DCs can also be pulsed with NDV oncolysate. Such cells
were superior in stimulating patients T-cells in ELISPOT assays
compared to DCs pulsed with tumor lysate without NDV (49).
GRAFTING OF AUTOLOGOUS ACTIVATED T-CELLS AND DC1 BACK TO
THE PATIENT
Our proposal for a multimodal cancer therapy involves the transfer
of immune T-cells and of DC1 as professional antigen-presenting
cells back to the patient. Activation of the tumor microenviron-
ment by low dose irradiation (LDI) (50) or by local hyperthermia
(LHT) (51) should improve tumor targeting of virus, T-cells,
and DCs (52). Tumor destruction by the activated T-cells should
release TAs, which would be taken up by co-injected DC1 to be
then cross-presented to naïve or memory T-cells.
HITCHHIKING OF NDV ON ACTIVATED T-CELLS: COMBINING CELL
THERAPY WITH VIRUS THERAPY
One way of further enhancement of the efficacy of this multimodal
therapy concept consists in the loading of the activated T-cells
with oncolytic NDV before grafting the cells back to the patient.
In a tumor neutralization assay in vitro, monolayers of human
tumor cells could be completely and effectively destroyed by the
addition of polyclonally activated human T-cells loaded with
oncolytic NDV (53). In this process, synergistic effects between
cytotoxic T-cells and oncolytic virus in the tumor contact zone
were apparent (53).
If activated T-cells are not available, a multimodal therapy could
also consist of the combination of LHT, systemic application of
oncolytic NDV and of DC1. Such approach resulted in long-term
remission of metastatic prostate cancer (52).
TARGETING AN INTRODUCED VIRAL ANTIGEN IN TUMOR TISSUE BY
GRAFTED T-CELLS AND DCs VIA CELL-BOUND TRI-SPECIFIC
ANTIBODIES
Table 1 summarizes five steps that are essential for a new adoptive
cellular cancer therapy strategy. Oncolytic NDV can be introduced
into tumor tissue of the patient by various means as discussed
before. The patients T-cells and DCs would be activated and polar-
ized also as discussed before. The tsAbs have three different binding
sites, each of which is only monovalent. To increase the avidity and
stability of the cell surface attached ts fusion protein, we propose
that two of the binding sites should bind to well-defined targets
on T-cells or DCs. The addendum of the table lists some of the
potential targets.
This approach is only meant as a perspective for the future
and has not been tested experimentally or clinically. There should
be a proper timing between virus-pretargeting of tumor tissue
(including metastases) and the cell therapy. We envisage that 24–
48 h after virus inoculation should be a good time period for
grafting the cells for a VA targeted therapy. Excessive virus should
Table 1 | Adoptive cellular cancer therapy: targeting a viral antigen
(e.g., HN) by graftedT-cells and DCs via cell-bound tri-specific
antibodies.
Step 1 Pre-conditioning of the tumor microenvironment in the patient
Step 2 Local or systemic application of oncolytic NDV for introduction
of the viral target antigen HN within the tumor tissue
Step 3 Universal activation ex vivo of the patients T-cells and loading
with tri-specific antibodies thus exposing multiple anti-HN
binding sites
Step 4 Generation of polarized DCs from the patient via infection by
NDV or pulsing with NDV oncolysate; loading of the DC1 with
tri-specific antibodies thus exposing multiple anti-HN binding
sites
Step 5 Grafting the T-cells and/or DCs to the pre-conditioned patient
Addendum:The tri-specific single-chain antibodies should bind with two
arms to targets on T cells or targets on DCs and expose the third arm
anti-HN
PotentialT-cell targets Potential DC targets
CD3 CD11c
CD28 CD205
CD25 CD40
CD2 CD80
CD44 CD16a
CD45 CD83
CD69 CD116
CXCR4 IFNAR
CD107a CD119
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be cleared by then and the tumor tissue should be infected and
expressing cell-bound VAs.
CONCLUDING REMARKS
We propose a multimodal approach for effective cancer therapy
because previous monomodal approaches of chemo- or radio-
therapy faced problems of tumor resistance mechanisms. Specific
immunotherapies targeted to specific TA faced similar problems of
tumor escape and resistance mechanism. There may be a long way
to get a multimodal therapy such as the one proposed and estab-
lished but we believe it is important to propose a viable perspective
for future orientation. Oncolytic viruses, T-cells, dendritic cells,
and bi-specific antibodies are all promising biologics whose intel-
ligent combination holds a lot of promise for future cancer therapy.
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